Tacrolimus combined with arsenic trioxide provides a three-in-one drug-eluting coronary stent integrating anti-restenosis, pro-endothelialization and anti-inflammation
The limitations of current drug-eluting stent technologies in selectively inhibiting vascular smooth muscle cell proliferation, which often leads to inflammation, call for innovative approaches in coronary artery disease treatment. In the present work, we propose a revolutionary solution: a three-in...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Medicine in Novel Technology and Devices |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590093524000055 |